Leukemia patients survive with stem cell transplant

November 24, 2004

CLEVELAND: A new study published in the New England Journal of Medicine confirms that stem cells derived from the umbilical cords of newborn babies are a viable and effective transplant source for thousands of leukemia patients who have no other treatment option.

"As many as 16,000 leukemia patients diagnosed each year require a bone marrow transplant, but have no matched relative or can't find a match in the national bone marrow registry," says Mary J. Laughlin, MD, lead author on the study and hematologist oncologist at Case Comprehensive Cancer Center and University Hospitals of Cleveland Ireland Cancer Center. "Umbilical cords that are normally discarded after birth could provide real hope for these patients."

Dr. Laughlin led an international team of researchers in collaboration with the International Bone Marrow Transplant Registry and the New York Blood Center National Cord Blood Program. They conducted an analysis and comparison of treatment results in more than 500 adult leukemia patients undergoing transplant.

Researchers directly compared patients who had cord blood stem cell transplants with two groups: patients who had fully-matched unrelated bone marrow transplants and patients who had one antigen-mismatched unrelated bone marrow transplants. The study included patient's ages 16 to 60 years who underwent transplants in the United States during a six-year period ending in 2001.

Survival rates were highest (33 percent) for those bone marrow transplants with matched unrelated donors. Survival rates were the same (22 percent) for cord blood and one antigen-mismatched unrelated bone marrow transplant patients--results that clearly indicate the efficacy of cord blood stem cells when bone marrow donors are unavailable, according to Dr. Laughlin, an Associate Professor of Medicine at Case Western Reserve University School of Medicine.

"These are very high risk patients who undergo cord blood transplants only as a last resort effort to stay alive," Dr. Laughlin says. "Even with a cord blood transplant, these patients often suffer from life-threatening infections. But the fact is, without attempting this innovative therapy, none of them would survive."

"Techniques that extend the availability of stem cell transplantation to those patients in desperate need are an important and valuable step in the right direction," said Marshall Lichtman, MD, The Leukemia & Lymphoma Society's Executive Vice President. "Dr. Laughlin's study gives renewed hope to adult patients without a sibling stem cell donor. Continued research is needed, however, to improve the outlook for the large proportion of patients who do not yet benefit from these approaches." The Society helped fund the study.

Cord blood transplantation provides leukemia patients with stem cells, enabling them to produce healthy blood cells in a procedure previously shown to be highly effective in children with the disease. As a stem cell source, umbilical cord blood is not controversial and readily available; in fact, cord blood is normally discarded after a baby's birth.

New mothers can donate cord blood immediately after delivery. Ordinarily, the placenta (the afterbirth), and the cord blood it contains, is discarded. Now a trained technician can collect the cord blood which remains in the placenta after the baby is born and the cord is cut. The donated cord blood is processed and frozen and stored for any patient in the future that might need a transplant.

The availability of cord blood makes it a logical choice for doctors and their patients when a matching bone marrow donor cannot be found. A patient's best chance for survival comes from a bone marrow donor who is related to the patient and matches the patient's tissue type. A bone marrow transplant from an unrelated donor may be an option when there is no donor available in the family, but offers a poorer chance for survival, even when fully matched.

"The fact is, approximately 20,000 leukemia patients nationwide need transplants but only 20 percent of them have a sibling match, so there remains a large group--about 16,000 patients--who are forced to seek donors from a marrow donor registry in hopes of finding a match from donors who aren't related to them," Dr. Laughlin says. "But only a small percentage of patients are lucky enough to find a transplant match at the registry, which is why the cord blood transplant is so important."

University Hospitals of Cleveland collaborates with the New York Blood Center National Cord Blood Program (a public cord blood bank that was the source of most of the cord blood units reported in the study) to collect cord blood donated for future patients. Recently, cord blood donated by the mother of a newborn baby at UHC proved a lifesaving option for a two-year-old leukemia patient.
-end-
The study was funded by the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, the National Heart Lung and Blood Institute, the Abraham and Phyllis Katz Foundation, The Leukemia & Lymphoma Society, American Society of Clinical Oncology and the Children's Leukemia Research Association.

University Hospitals of Cleveland

Related Stem Cells Articles from Brightsurf:

SUTD researchers create heart cells from stem cells using 3D printing
SUTD researchers 3D printed a micro-scaled physical device to demonstrate a new level of control in the directed differentiation of stem cells, enhancing the production of cardiomyocytes.

More selective elimination of leukemia stem cells and blood stem cells
Hematopoietic stem cells from a healthy donor can help patients suffering from acute leukemia.

Computer simulations visualize how DNA is recognized to convert cells into stem cells
Researchers of the Hubrecht Institute (KNAW - The Netherlands) and the Max Planck Institute in Münster (Germany) have revealed how an essential protein helps to activate genomic DNA during the conversion of regular adult human cells into stem cells.

First events in stem cells becoming specialized cells needed for organ development
Cell biologists at the University of Toronto shed light on the very first step stem cells go through to turn into the specialized cells that make up organs.

Surprising research result: All immature cells can develop into stem cells
New sensational study conducted at the University of Copenhagen disproves traditional knowledge of stem cell development.

The development of brain stem cells into new nerve cells and why this can lead to cancer
Stem cells are true Jacks-of-all-trades of our bodies, as they can turn into the many different cell types of all organs.

Healthy blood stem cells have as many DNA mutations as leukemic cells
Researchers from the Princess Máxima Center for Pediatric Oncology have shown that the number of mutations in healthy and leukemic blood stem cells does not differ.

New method grows brain cells from stem cells quickly and efficiently
Researchers at Lund University in Sweden have developed a faster method to generate functional brain cells, called astrocytes, from embryonic stem cells.

NUS researchers confine mature cells to turn them into stem cells
Recent research led by Professor G.V. Shivashankar of the Mechanobiology Institute at the National University of Singapore and the FIRC Institute of Molecular Oncology in Italy, has revealed that mature cells can be reprogrammed into re-deployable stem cells without direct genetic modification -- by confining them to a defined geometric space for an extended period of time.

Researchers develop a new method for turning skin cells into pluripotent stem cells
Researchers at the University of Helsinki, Finland, and Karolinska Institutet, Sweden, have for the first time succeeded in converting human skin cells into pluripotent stem cells by activating the cell's own genes.

Read More: Stem Cells News and Stem Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.